Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study
Open Access
- 9 February 2024
- journal article
- research article
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 31, 100693
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute
- National Center for Advancing Translational Sciences
- National Institute of Child Health and Human Development
- National Institutes of Health
This publication has 26 references indexed in Scilit:
- Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk PatientsClinical Infectious Diseases, 2022
- Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 OutpatientsThe Journal of Infectious Diseases, 2022
- Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort studyThe Lancet, 2022
- Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regressionThe Lancet, 2022
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19New England Journal of Medicine, 2022
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19Science, 2021
- Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort CollaborativeJAMA Network Open, 2021
- Firth's logistic regression with rare events: accurate effect estimates and predictions?Statistics in Medicine, 2017
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983